June 29, 2017 6:20pm

 

Wiping out strength and applying weakness

One session down, one session up after a session down following three (3) up sessions

 

As I stated, the seesaw’s pivot was weighted to sellers

 

Pre-open indications re-cap: 3 hit (BLUE, HSGX and OSIR) and 2 miss (JUNO and KITE)

 

The IBB was down -1.43%, XBI -1.29%, XLV -0.91%, IWM-0.59% while the VIX was UP +14.06%,  

 

Out and about: Sangamo Therapeutics (SGMO) appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors

 

I answer one question, in which company should investors commit and keep their money.

 

Thursday’s results have implications to Friday’s sector activity.  

 

 

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative with an A/DL of 17/25 and 1 flat;

·         The mid-day was negative with an A/DL of 9/32 and 2 flats;

·         The close was negative with an A/DL of 13/28 and 2 flats;

 

 

Pre-open indications re-cap:  3 hit and 2 miss

  • bluebird bio (BLUE) closed down -$0.85 – hit;
  • Histogenics (HSGX) closed up +$0.04 – hit;
  • Juno Therapeutics (JUNO) closed down -$1.15 – miss;
  • Kite Pharma (KITE) closed down -$0.06 – miss;
  • Osiris (OSIR) closed down -$0.43 – hit;

 

 

Henry’omics:

From the pre-open’s investor’s newsletter …” the seesaw … as sector end goes up and down. Where is the pivot set for buyers and sellers?

  • Reiterating, “My view is toward sellers.”

The cell therapy sector’s record over the last 6 sessions (of 43 covered companies):

·         Thursday closed NEGATIVE with 28 decliners, y13advancers and 2 flats;

·         Wednesday closed POSITIVE with 9 decliners, 31 advancers and 3 flats;

·         Tuesday closed NEGATIVE with 32 decliners, 10 advancers and 1 flat;

·         Monday closed POSITIVE with 15 decliners, 26 advancers and 2 flats;

·         Friday closed POSITIVE with 14 decliners, 24 advancers and 5 flats;

·         Last Thursday closed POSITIVE with 12 decliners, 27 advancers and 4 flats

 

And it … CAME THROUGH!

 

 

Out and about:

Sangamo Therapeutics (SGMO) today announced the appointment of Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to the Company's Board of Directors.

·         Dr. Jeffs currently serves as a Senior Advisor to United Therapeutics Corp., where he worked for 18 years, most recently as President and co-CEO. He has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products. Prior to joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics and Dova Pharmaceuticals. He received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina.

·         Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.

SGMO closed DOWN -$0.15 or -1.66% to $8.90

 

 

Daily analytics:

U.S. stocks tumbled on Thursday, with the Dow on track for its biggest one-day drop in more than a month as the cell therapy sector sold-off.  The Dow fell 164 points, or 0.8%, to 21,290, its biggest percentage decline since May 17. The S&P 500 index SPX, dropped 22 points, or 0.9%, to 2,418. The NASDAQ tumbled 111 points or 1.8% to 6,122 which is on track for its third straight session with a move of 1%, including a slump of 1.6% on Tuesday and Wednesday’s 1.4% rally—its biggest one-day rise since Nov. 7.

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 11.44 … up +14.06%

·Wednesday traded near 10.05 … DOWN -9.13% after Tuesday traded above 11.07 … up +11.72%, Monday traded near 9.7, breaking below 10 for the first time since June 9, Friday’s near 10.02 … down -4.39% and last Thursday’s near 10.5

 

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a close of:

·         Thursday traded DOWN -0.59%

·         Wednesday +1.53%

·         Tuesday -0.88%

·         Monday+0.12%

·         Friday+0.66%

·         Last Thursday +0.38%

… The iShares NASDAQ Biotechnology (IBB) indicated a close of:

·         Thursday traded DOWN -1.43%

·         Wednesday +1.93%

·         Tuesday -2.88%

·         Monday -0.32%

·         Friday+0.20%

·         Last Thursday +1.27%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %’s migrate……….

·         Thursday’s decliners ranged from -0.06% <KITE> to -9.72% <BLCM> in  28  equities;

·         Wednesday’s decliners ranged from -0.56% <HSGX> to -4.63% <ADVM> in  9  equities;

·         Tuesday’s decliners ranged from -0.32% <BTX> to -9.95% <CUR> in  32  equities;

·         Monday’s decliners ranged from -0.23% <KITE> to -3.93% <NWBO> in  15  equities;

·         Friday’s decliners ranged from -0.31% <FATE> to -11.36% <BSTG> in  14  equities;

·         Last Thursday’s decliners ranged from -0.38% <MDXG> to -5.95% <ATHX> in  12  equities;

Versus

………… look at the percentage’s (%) and their decreases …….

·         Thursday’s gainers ranged from +0.24%  <BCLI> to +27.71% <BSTG> in 13 equities;

·         Wednesday’s gainers ranged from +0.22%  <CLBS> to +9.67% <FCSC> in 31 equities;

·         Tuesday’s gainers ranged from +0.55%  <VTGN> to +14.49% <FCSC> in 10 equities;

·         Monday’s gainers ranged from +0.08%  <XON> to +10.41% <CAPR> in 26 equities;

·         Friday’s gainers ranged from +0.28%  <XON> to +7.49% <JUNO> in 24 equities;

·         Last Thursday’s gainers ranged from +0.31%  <FATE> to +14.74% <NWBO> in 27 equities;

 

 

Some of MY working trend lines or indications for Friday:

… The greatest volume to the downside:  BLCM, NWBO, JUNO, KITE and CYTX

… Upside volume was weighted to:  BSTG, VCEL, FATE, ADRO and QURE

… Biggest $ downside:  ONCE, BLCM, JUNO, KITE and XON

… Largest $ upside: ADRO, AXGN, MESO, QURE, and VCEL          

… Flat: VTGN and BLFS

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.